Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

UFT in bladder cancer.

Y Kubota1, S Noguchi, M Hosaka

  • 1Department of Urology, Yokohama City University, School of Medicine, Japan.

Oncology (Williston Park, N.Y.)
|August 12, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Frequency-domain interferometry for the determination of time delay between two extreme-ultraviolet wave packets generated by a tandem undulator.

Scientific reports·2023
Same author

Double-pulsed wave packets in spontaneous radiation from a tandem undulator.

Scientific reports·2022
Same author

Helical Phase Structure of Radiation from an Electron in Circular Motion.

Scientific reports·2017
Same author

Angular Momentum of Twisted Radiation from an Electron in Spiral Motion.

Physical review letters·2017
Same author

Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology.

ESMO open·2016
Same author

Living situations associated with poor dietary intake among healthy Japanese elderly: the Ohasama Study.

The journal of nutrition, health & aging·2015
Same journal

Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.

Oncology (Williston Park, N.Y.)·2026
Same journal

Access to Care and the Affordable Care Act: Why Do Problems Exist 15 Years Later?

Oncology (Williston Park, N.Y.)·2026
Same journal

Synchronous Endometrial and Ovarian Cancers: A Case Study and Literature Review.

Oncology (Williston Park, N.Y.)·2026
Same journal

Perceived Social Support, Anxiety, and Depression Among Women With Breast Cancer.

Oncology (Williston Park, N.Y.)·2026
Same journal

Before Certainty.

Oncology (Williston Park, N.Y.)·2026
Same journal

Adult T-Cell Leukemia/Lymphoma and Epstein-Barr Virus-Positive DLBCL: A Rare Concomitant Association.

Oncology (Williston Park, N.Y.)·2026
See all related articles

UFT (uracil and tegafur) effectively prevents superficial bladder cancer recurrence when used as adjuvant chemotherapy. This oral treatment shows mild toxicity, making it a viable option for bladder cancer management.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • UFT, a combination of uracil and tegafur (a 5-fluorouracil prodrug), is utilized in Japan for bladder cancer treatment and adjuvant chemotherapy.
  • Phase II studies demonstrated UFT's efficacy with a 32% overall response rate, including 19% complete response, at doses of 300-600 mg/day.

Purpose of the Study:

  • To evaluate the efficacy of long-term oral UFT (300-400 mg/day for 2 years) in preventing intravesical recurrence of superficial bladder cancer as adjuvant chemotherapy.
  • To assess the toxicity profile of long-term UFT administration in this patient population.

Main Methods:

  • A randomized, prospective trial was conducted.
  • Patients received oral UFT as adjuvant chemotherapy for superficial bladder cancer following transurethral resection.
  • Treatment duration was 2 years with daily UFT doses ranging from 300 to 400 mg.

Related Experiment Videos

Main Results:

  • Long-term UFT administration significantly prevented the recurrence of superficial bladder cancer.
  • The observed toxicity was generally mild and reversible.
  • Gastrointestinal toxicity was dose-dependent, affecting 56% at 600 mg/day and 24% at 300 mg/day in earlier studies.

Conclusions:

  • Oral UFT is an effective single agent for preventing superficial bladder cancer recurrence when used as adjuvant therapy.
  • UFT demonstrates acceptably low toxicity, particularly when administered at appropriate doses (300-400 mg/day).
  • Proper usage of UFT suggests a favorable risk-benefit profile for bladder cancer management.